Crispr Therapeutics AG (CRSP) earnings · last reported Nov 2, 2026
Next report
Around Thu, Feb 11, 2027
In 99 days · quarter ending Dec 2026
Not announced yet. Lician projection, not a company or provider date: the same quarter’s report a year ago plus 52 weeks.
Follow CRSP into its report
Save it to a free watchlist (no card). Alerts when the date moves or results land are part of Pro.
Earnings move
- Options price in
- — No upcoming report date.
- Average move after earnings
- ±5.9% Absolute close-to-close move, 3 reports
Options-implied move: the at-the-money straddle (call + put) on the first expiry after the report, divided by the stock’s close, from EODHD end-of-day option chains. It is what the options market prices as the absolute move to that expiry, not a forecast of direction. Move: close before the news → close after it (before the open: prior close → report-day close; after the close: report-day close → next close), adjusted for splits and dividends, from EODHD end-of-day prices. Reports with an unannounced time are not averaged: both candidate moves are stored instead. Per-report moves, gaps, moves vs SPY and the sector, beat/miss asymmetry and implied vs actual are in Lician Pro below.
Latest result
EPSGAAP
−$1.15
vs −$1.06 est. −8.5%
GAAP diluted EPS, SEC 10-Q
Revenue
—
vs $16.56M est. —
EPS actuals are checked against the SEC filing and the company’s earnings press release (8-K EX-99.1). A company that reports only GAAP EPS is graded on its SEC diluted EPS; one that reports adjusted EPS is graded on the provider’s adjusted figure when the release confirms it. A figure that matches neither is shown as unverified, with no beat or miss. Revenue actuals come from the SEC filing of the same quarter where we have it.
Beat / miss history
- Beat EPS in 2 of 4
- Nov 2, 2026MissEPS −$1.15GAAP vs −$1.06 −8.5%Rev — vs $16.56M
- Aug 3, 2026BeatEPS −$0.94GAAP vs −$1.10 +14.5%Rev $10.18M vs $7.43M +37.0%
- May 4, 2026MissEPS −$1.28GAAP vs −$1.23 −4.1%Rev $1.46M vs $4.25M −65.7%
- Nov 10, 2025BeatEPS −$1.17GAAP vs −$1.29 +9.3%Rev $889.00K vs $8.95M −90.1%
| Reported | Quarter | EPS est. | EPS actual | Surprise | Revenue est. | Revenue | Surprise |
|---|---|---|---|---|---|---|---|
| Nov 2, 2026 | Sep 2026 | −$1.06 | −$1.15GAAP | −8.5% | $16.56M | — | — |
| Aug 3, 2026 | Jun 2026 | −$1.10 | −$0.94GAAP | +14.5% | $7.43M | $10.18MSEC | +37.0% |
| May 4, 2026 | Mar 2026 | −$1.23 | −$1.28GAAP | −4.1% | $4.25M | $1.46MSEC | −65.7% |
| Nov 10, 2025 | Sep 2025 | −$1.29 | −$1.17GAAP | +9.3% | $8.95M | $889.00KSEC | −90.1% |
Earnings documents
- Earnings press releaseEX-99.1 · 8-K filed Nov 2, 2026Open on SEC.gov
Read the filing on LicianEDGAR filing index
Documents link to SEC EDGAR. Lician does not publish earnings-call transcripts.
Healthcare peers with similar quant ratings
CRSP is rated 1.61 of 5 among 532 rated Healthcare stocks (Lician quant rating, Nov 4, 2026). How the rating works
- GLSI earnings1.64 · Sell · stock
- KRRO earnings1.64 · Sell · stock
- OCUL earnings1.63 · Sell · stock
- KYTX earnings1.62 · Sell · stock
- STRO earnings1.61 · Sell · stock
- ANGO earnings1.60 · Sell · stock
- ACHV earnings1.59 · Sell · stock
- SRRK earnings1.58 · Sell · stock
| Quarter | Revenue | EPS | YoY |
|---|---|---|---|
| Q2 FY26 | $10.18M | −$0.94 | +1041.4% |
| Q1 FY26 | $1.46M | −$1.28 | +68.6% |
| Q3 FY25 | $889.00K | −$1.17 | +47.7% |
| Q2 FY25 | $892.00K | −$2.40 | +72.5% |
Crispr Therapeutics AG (CRSP) is a biotechnology company listed on US.
Latest reported CRSP revenue for 2025-12-31 was $3.5M. Net income was -$581.6M. Revenue was down 90.6% from 2024-12-31 to 2025-12-31. CRSP currently screens at market cap $5.42B.
When the next CRSP 8-K Item 2.02 lands, this page should move. Until then the SEC archive is the source.
The change that matters: Revenue was down 90.6% from 2024-12-31 to 2025-12-31. An earnings headline that ignores that move is noise.
Not investment advice. Full CRSP research stays on the stock page; the tape stays on the quote page.
CRSP earnings FAQ
When is CRSP's next earnings date?
Crispr Therapeutics AG (CRSP) has not announced it yet. Lician estimates the next report around Feb 11, 2027, based on the date it reported the same quarter a year ago. This is an estimate, not a confirmed date; the page updates when the provider lists one.
Did CRSP beat earnings estimates last quarter?
No. On Nov 2, 2026 Crispr Therapeutics AG (CRSP) reported adjusted EPS of −$1.15 against a −$1.06 consensus (−8.5%), a miss.
How often does CRSP beat EPS estimates?
Crispr Therapeutics AG (CRSP) beat the EPS consensus in 3 of its last 9 reported quarters. Revenue beat the consensus in 1 of the last 3 quarters with an estimate on file.
What are CRSP's latest revenue and net income?
Latest cached Crispr Therapeutics AG (CRSP) revenue for Dec 31, 2025 was $3.5M. Net income was -$581.6M. Statements: https://lician.com/financials/crsp
What is CRSP's latest diluted EPS?
Latest cached Crispr Therapeutics AG (CRSP) diluted EPS for Dec 31, 2025 was -$6.47.
What period does the latest CRSP earnings print cover?
The latest cached Crispr Therapeutics AG (CRSP) earnings print covers Dec 31, 2025. The prior cached period on this page is Dec 31, 2024.
How did CRSP revenue change from the prior cached period?
Cached Crispr Therapeutics AG (CRSP) revenue was down 90.6% from $37.3M (Dec 31, 2024) to $3.5M (Dec 31, 2025). Statements: https://lician.com/financials/crsp
Where are CRSP earnings listed?
Cached earnings facts for Crispr Therapeutics AG (CRSP) are listed at https://lician.com/earnings/crsp. Statements: https://lician.com/financials/crsp
Not investment advice.